Anavex Life Sciences Corp. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
45.43 M |
Public Float |
42.13 M |
Anavex Life Sciences Corp. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.51 |
Market Cap |
$174.92 M |
Shares Outstanding |
50.41 M |
Public Float |
44.54 M |
Address |
51 West 52nd Street New York New York 10019 United States |
Employees | - |
Website | http://www.anavex.com |
Updated | 07/08/2019 |
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY. |